Diabetes and prognosis in a breast cancer cohort

[1]  R. Smith,et al.  Breast cancer epidemiology. , 2018 .

[2]  Mong-Hong Lee,et al.  The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth , 2010, Journal of cellular and molecular medicine.

[3]  M. Inoue,et al.  Insulin resistance and cancer: Epidemiological evidence , 2010, Cancer science.

[4]  D. Rose,et al.  Interaction between menopausal status and obesity in affecting breast cancer risk. , 2010, Maturitas.

[5]  C. Rock,et al.  Medical comorbidities predict mortality in women with a history of early stage breast cancer , 2010, Breast Cancer Research and Treatment.

[6]  D. Rose,et al.  Influence of obesity on breast cancer receptor status and prognosis , 2009, Expert Review of Anticancer Therapy.

[7]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Donghui Li,et al.  Premenopausal Breast Cancer: Estrogen Receptor Status and Insulin‐Like Growth Factor‐I (IGF‐I), Insulin‐Like Growth Factor Binding Protein‐3 (IGFBP‐3), and Leptin , 2009, The breast journal.

[9]  Adrian V. Lee,et al.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. , 2009, Endocrine reviews.

[10]  Thomas E Rohan,et al.  Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. , 2009, Journal of the National Cancer Institute.

[11]  A. Wolff,et al.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.

[12]  D. Leroith,et al.  Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[13]  M. Castiglione,et al.  Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  B. Zinman,et al.  The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.

[15]  R. Langer,et al.  Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. , 2008, Archives of internal medicine.

[16]  D. Rose,et al.  Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer , 2007, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[17]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[18]  Robert M Elashoff,et al.  Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. , 2007, Journal of the National Cancer Institute.

[19]  R. Blamey,et al.  EUSOMA accreditation of breast units. , 2006, European journal of cancer.

[20]  Siegal Sadetzki,et al.  Diabetes mellitus and breast cancer. , 2005, The Lancet. Oncology.

[21]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[22]  V. G. Pigmans,et al.  Diabetes Mellitus Type 2 , 2004, Journal of the Epidemiology Foundation of India.

[23]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[24]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[25]  F. Pi‐Sunyer,et al.  Obesity and type 2 diabetes. , 2003, Endocrinology and metabolism clinics of North America.

[26]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[27]  E. Bonora,et al.  Mortality from site-specific malignancies in type 2 diabetic patients from Verona. , 2003, Diabetes care.

[28]  D. Rose,et al.  Breast Cancer and Obesity: An Update , 2003, Nutrition and cancer.

[29]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Porter,et al.  Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma , 2001, Cancer.

[31]  E. Reiter,et al.  Growth hormone , 1993 .

[32]  M. La Guardia,et al.  Breast cancer and obesity. , 2001, Panminerva medica.

[33]  A. Green,et al.  Cancer and diabetes ‐ a follow‐up study of two populationbased cohorts of diabetic patients , 1997, Journal of internal medicine.

[34]  S. Greenland,et al.  A Meta‐analysis of Body Mass Index and Risk of Premenopausal Breast Cancer , 1995, Epidemiology.

[35]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[36]  R. Elashoff,et al.  Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  N. Boyd,et al.  Body size and breast cancer prognosis: A critical review of the evidence , 1990, Breast Cancer Research and Treatment.

[38]  G. Bray,et al.  Obesity: definition, diagnosis and disadvantages , 1985, The Medical journal of Australia.

[39]  K. Kliche,et al.  Premenopausal Breast Cancer , 2012, Drugs.

[40]  R. Kaaks,et al.  Diabetes mellitus type 2 - an independent risk factor for cancer? , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[41]  B. Jasani,et al.  ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS , 2009 .

[42]  L. Pollack,et al.  Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer , 2005, Nature Clinical Practice Oncology.

[43]  I. G. Fantus,et al.  Insulin and related factors in premenopausal breast cancer risk , 2004, Breast Cancer Research and Treatment.

[44]  B. Hoffman,et al.  Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study , 2002 .

[45]  B. Hoffman,et al.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.